Zynex (NASDAQ:ZYXI – Get Free Report) updated its third quarter 2024 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 0.050- for the period, compared to the consensus estimate of 0.160. The company issued revenue guidance of $50.0 million-, compared to the consensus revenue estimate of $60.2 million. Zynex also updated its FY 2024 guidance to 0.200- EPS.
Analysts Set New Price Targets
Several research analysts have recently weighed in on the company. HC Wainwright restated a buy rating and issued a $21.00 price target on shares of Zynex in a research note on Wednesday, May 1st. Royal Bank of Canada restated an outperform rating and issued a $15.00 price target on shares of Zynex in a research note on Friday, June 14th.
Read Our Latest Stock Analysis on Zynex
Zynex Stock Performance
Zynex Company Profile
Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.
See Also
- Five stocks we like better than Zynex
- How to Calculate Options Profits
- Viking Therapeutics: Pharma Stock Soars on Positive Earnings
- How to invest in marijuana stocks in 7 stepsĀ
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.